Glenmark Receives US FDA Approval to Expand RYALTRIS Nasal Spray Use to Younger Children
Glenmark Pharmaceuticals has received US FDA approval to expand the use of its RYALTRIS nasal spray for treating Seasonal Allergic Rhinitis symptoms in children aged 6 to under 12 years. Previously approved for adults and patients 12 years and older, this fixed-dose combination of olopatadine hydrochloride and mometasone furoate now covers a younger pediatric group. The approval enhances access to this treatment in the US and strengthens Glenmark's respiratory portfolio, with RYALTRIS also approved in multiple global markets.
First-hand measurement across 3 sources
We measured how 3 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is neutral (55/100). Lens Score 38/100.
Outlets measured: economictimes, news18, businessstandard. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (55–55/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
businessstandard broke this story on 21 Jul, 04:36 am. Other outlets followed.